New study tracks mylotarg safety in AML patients
NCT ID NCT05189639
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is monitoring the safety and effects of Mylotarg in 165 adults in Korea who are newly diagnosed with acute myeloid leukemia (AML). Participants will receive Mylotarg as part of their routine care, and researchers will track any side effects and how the disease responds. The goal is to better understand the drug's safety and effectiveness in real-world settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mylotarg (gemtuzumab ozogamicin)
What this could lead to
If successful, this study could confirm that Mylotarg is a safe and effective treatment option for adults with newly diagnosed acute myeloid leukemia.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects like serious infections are possible, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul national university hospital
RECRUITINGSeoul, South Korea